MedTrace Logo

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

NCT05802329 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-12-03

No results posted yet for this study

Summary

A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema

Conditions

Interventions

DRUG

OCU200

Intravitreal Injection

Sponsors & Collaborators

Principal Investigators

  • Huma Qamar, MD, MPH, CMI · Ocugen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-13
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05802329 on ClinicalTrials.gov